Maintenance treatment for type 1 autoimmune pancreatitis: effectiveness and development of the PrescrAIP relapse prediction model.
Lanzillotta M, Macinga P, Poulsen JL, Vinge-Holmquist O, Demirci AF, Tacelli M, Backhus J, Algül H, Descourvieres C, Kiriukova M, Goni E, Hollenbach M, Miksch RC, Kunovsky L, Vujasinovic M, Nikolic S, Dickerson L, Hirth M, Neurath MF, Zumblick M, Vila J, Jalal M, Beyer G, Frost F, Carrara S, Kala Z, Jabandziev P, Sisman G, Akyuz F, Capurso G, Falconi M, Arlt A, Vleggaar FP, Barresi L, Greenhalf B, Czakó L, Hegyi P, Hopper A, Nayar MK, Gress TM, Vitali F, Schneider A, Halloran CM, Trna J, Okhlobystin AV, Dagna L, Cahen DL, Bordin D, Rebours V, Mayerle J, Kahraman A, Rasch S, Culver E, Kleger A, Martínez-Moneo E, Hucl T, Olesen SS, Bruno MJ, Beuers U, Della-Torre E, Löhr JM, Rosendahl J, Overbeek KA; PrescrAIP Study Group.
Lanzillotta M, et al. Among authors: hopper a.
Clin Gastroenterol Hepatol. 2025 Sep 13:S1542-3565(25)00795-5. doi: 10.1016/j.cgh.2025.09.005. Online ahead of print.
Clin Gastroenterol Hepatol. 2025.
PMID: 40953780